Methylenetetrahydrofolate reductase gene polymorphism, homocysteine nd risk of macroangiopathy in Type 2 diabetes mellitus

Journal of Endocrinological Investigation

Volumn 29, Issue 9, 2006, Pages 814-820

  Sun, J ^a   Xu, Y ^a   Zhu, Y ^a   Lu, H ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Genetics; Macroangiopathy homocysteine; Methylenetetrahydrofolate reductase; Type 2 diabetes mellitus

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE; HOMOCYSTEINE; VALINE;

ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CASE CONTROL STUDY; CHINESE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DISEASE MARKER; DOPPLER ECHOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FLUORESCENCE ANALYSIS; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HEART INFARCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PREDICTION; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT;

EID: 33845288641     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347376     Document Type: Article

References (40)

1. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999, 354: 407-13.
2. Stehouwer CDA, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJM, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 1998, 18: 1895-901.
3. Frosst P, Bloom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995, 10: 111-3.
4. Kluijtmans LAJ, Vanden LPWJ, Boers GHJ. Moleuclar genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996, 58: 35-41.
5. Bockxmear FM, Mamolte CDS, Vasikaram SD. Methylenetrahydrofolate reductase gene and coronary heart disease. Circulation 1997, 95: 21-4.
6. Agullo-Ortuno MT, Albaladejo MD, Parra S, et al. Plasmatic homocysteine concentration and its relationship with complications associated to diabetes mellitus. Clin Chim Acta 2002, 326: 105-12.
7. Hasegawa G, Obayashi H, Kamiuchi K, et al. The association between end-stage diabetic nephropathy and methylenetetrahydrofolate reductase genotype with macroangiopathy in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2003, 111: 132-8.
8. Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: Effect of parenteral methylcobalamin treatment. Atherosclerosis 1993, 103: 149-57.
9. Jacobsen DW, Gatautis VJ, Green R. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 1994, 40: 873-81.
10. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJC, Jakobs C. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus a population-based study. Arterioscler Thromb Vasc Biol 1998, 18: 133-8.
11. Yeromenko Y, Lavie L, Levy Y. Homocysteine and cardiovascular risk in patients with diabetes mellitus. Nutr Metab Cardiovasc Dis 2001, 11: 108-16.
12. Audelin MC, Genest J. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 2001, 159: 497-511.
13. Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 1998, 62: 1258-60.
14. Smulders Y, Rakic M, Slaats E, et al. Fasting and post-methionine homocysteine levels in NIDDM: determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999, 22: 125-32.
15. Fujita H, Narita T, Meguro H, et al. No association between MTHFR gene polymorphism and diabetic nephropathy in Japanese type II diabetic patients with proliferative diabetic retinopathy. J Diabetes Complications 1999, 13: 284-7.
16. Helfenstein T, Fonsecaa FA, Revals WG, et al. Prevalence of myocardial infarction is related to hyperhomocysteinemia but not influenced by C677T methylenetetrahydrofolate reductase and A2756G methionine synthase polymorphisms in diabetic and non-diabetic subjects. Clin Chim Acta 2005, 355: 165-72.
17. Scaglione L, Gambino R, Rolfo E, et al. Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media thickness in Italian type 2 diabetic patients. Eur J Clin Invest 2002, 32: 24-8.
18. Gudnason V, Stansbie D, Scott J, et al. C677T polymorphism in methylenetetrahydrofolate reductase: its frequency and impact on plasma homocysteine concentration in different European populations. Atherosclerosis 1998, 136: 347-54.
19. 12 concentration and risk for early-onset coronary heart disease. Am J Clin Nutr 1994, 9: 940-8.
20. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998, 64: 169-72.
21. Kang SS, Wong PW. Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia. Atherosclerosis 1996, 119: 135-8.
22. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996, 93: 7-9.
23. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians. Circulation 1996, 94: 2410-6.
24. Verhoef P, Kok FJ, Kluijtmans LA, et al. The 677CT mutation in the methylenetetrahydrofolate reductase gene: Associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 1997, 132: 105-13.
25. Tokgozoglu SL, Alikasifoglu M, Unsal, et al. Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary heart disease in a population with low plasma folate. Heart 1999, 81: 518-22.
26. Mager A, Lalezari S, Shohat T, et al. Methylenetetrahydrofolate reductase genotypes and early-onset coronary heart disease. Circulation 1999, 100: 2406-10.
27. Šimon J, Mayer O, Rosolová H. The influence of folates, B12 vitamin and lifestyle factors in mild hyperhomocysteinemia in a population sample. Cas Lék Ces 1999, 21: 650-3.
28. Bostom AG, Shemin D, Lapane, K, et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995, 114: 93-103.
29. Chauveau P, Chadefaux B, Coude M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993, 41: 72-7.
30. Agardh CD, Agardh E, Andersson A, Hultberg B. Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1994, 54: 637-41.
31. Wollesen F, Brattstrom L, Refsum H, et al. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999, 55: 1028-35.
32. Stabler S, Estacio R, Jeffers B, Cohen J, Allen R, Schrier R. Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. Metabolism 1999, 48: 1096-101.
33. Hofmann MA, Kohl B, Zumbach MS, et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1997, 20: 1880-6.
34. Chico A, Perez A, Cordoba A, et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998, 41: 684-93.
35. Lanfredini M, Fiorina P, Peca MG, et al. Fasting and postmethionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin dependent diabetes mellitus patients. Metabolism 1998, 47: 915-21.
36. Arruda VR, von-Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala677-Val in the methylenetetrahydrofolate reductase gene:a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997, 77: 818-21.
37. Outinen PA, Sood SK, Liaw PC, et al. Characterization of the stress-inducing effects of homocysteine. Biochem 1998, 332: 213-21.
38. Upchurch GRJ, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997, 272: 17012-7.
39. F. Landgren, B. Isralsson, A. Lindgren. Plasma homocysteine in actue myocardial infarction: homocyteine-lowering effect of folic acid. J Intern Med 1995, 237: 381-8.
40. 12, folate and vitamin B6 supplements in elderly people with normal serum vitamin concentration. Lancet 1995, 346: 85-9.